RMD Stock Recent News
RMD LATEST HEADLINES
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.
ResMed (RMD 1.89%), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion.
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago.
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com